Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients

PURPOSE: Diarrhea in relation to the lapatinib–capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamucci, T., Moscetti, L., Mentuccia, L., Pizzuti, L., Mauri, M., Zampa, G., Pavese, I., Sperduti, I., Vaccaro, A., Vici, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895217/
https://www.ncbi.nlm.nih.gov/pubmed/24292401
http://dx.doi.org/10.1007/s00432-013-1556-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895217/
https://www.ncbi.nlm.nih.gov/pubmed/24292401
http://dx.doi.org/10.1007/s00432-013-1556-4

Ejemplares similares